We have observed
11 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 or A2 publication dated after October 22, 2014).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
USE OF NEUREGULIN TO TREAT PERIPHERAL NERVE INJURY
PERFORIN INHIBITING BENZENESULFONAMIDE COMPOUNDS, PREPARATION AND USES THEREOF
THERAPEUTIC DOSING OF A NEUREGULIN OR A FRAGMENT THEREOF FOR TREATMENT OR PROPHYLAXIS OF HEART FAILURE
FORM 2 CRYSTALLINE POLYMORPH OF A SALT OF N-[1-6-(ETHYNYL-3-OXO-HEXAHYDRO-FURO[3,2-B]PYRROLE-4-CARBONYL)-3-METHYL-BUTYL]-4-[5-FLUORO-2-(4-METHYL-PIPERAZINYL)THIAZOL-4-YL]-BENZAMIDE USEFUL AS CYSTEINE PROTEASE INHIBITOR
HCV POLYMERASE INHIBITORS
DIOXOLANE ANALOGUES OF URIDINE FOR THE TREATMENT OF CANCER
METHODS FOR THE PREPARATION OF DIASTEREOMERICALLY PURE PHOSPHORAMIDATE PRODRUGS
NUCLEOTIDE PHOSPHORAMIDATE FORMULATION
BILE ACID BIOMARKERS FOR NIEMANN-PICK DISEASES, METHODS AND USES THEREFOR